Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Schultes
Birgit C
BC
Smith
L Mary
LM
Nicodemus
Christopher F
CF
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018394:CA-125 Antigen / Q000737:chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007107:Immune System; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018394:CA-125 Antigen; C518318:abagovomab